The Michigan Clinical Research Institute is currently enrolling those who have been diagnosed with GAD, and have received inadequate response from their current treatment.
An individual may qualify for the study if they:
- Are 18 years of age or older
- Have been diagnosed with General Anxiety Disorder (GAD)
- Currently having an inadequate response to one of the following GAD-approved treatments:
Paroxetine (Aropax®, Paxil®, Pexeva®, Seroxat®, Sereupin®, Brisdelle®), Venlafaxine XR (Effexor XR®), Duloxetine (Cymbalta®, Yentreve®), Escitalopram (Lexapro®, Cipralex®), Buspirone (BuSpar®)
Reimbursement for reasonable, out-of-pocket expenses such as travel and accommodations may be available to qualified individuals.
Contact us or fill out the form below so we can reach out to you and move forward with pre-screening questions to assess your overall eligibility.